- Home
- SGRP vs SCYX Comparison
SGRP vs SCYX Comparison
Compare SGRP & SCYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SGRP
- SCYX
- Stock Information
- Founded
- SGRP 1967
- SCYX 1999
- Country
- SGRP United States
- SCYX United States
- Employees
- SGRP N/A
- SCYX N/A
- Industry
- SGRP Business Services
- SCYX Biotechnology: Pharmaceutical Preparations
- Sector
- SGRP Consumer Discretionary
- SCYX Health Care
- Exchange
- SGRP Nasdaq
- SCYX Nasdaq
- Market Cap
- SGRP 56.8M
- SCYX 50.3M
- IPO Year
- SGRP 1996
- SCYX 2014
- Fundamental
- Price
- SGRP $2.25
- SCYX $1.20
- Analyst Decision
- SGRP
- SCYX Buy
- Analyst Count
- SGRP 0
- SCYX 1
- Target Price
- SGRP N/A
- SCYX N/A
- AVG Volume (30 Days)
- SGRP 97.1K
- SCYX 185.1K
- Earning Date
- SGRP 11-26-2024
- SCYX 11-06-2024
- Dividend Yield
- SGRP N/A
- SCYX N/A
- EPS Growth
- SGRP N/A
- SCYX N/A
- EPS
- SGRP 0.50
- SCYX N/A
- Revenue
- SGRP $228,869,000.00
- SCYX $8,566,000.00
- Revenue This Year
- SGRP N/A
- SCYX N/A
- Revenue Next Year
- SGRP N/A
- SCYX $145.59
- P/E Ratio
- SGRP $4.54
- SCYX N/A
- Revenue Growth
- SGRP N/A
- SCYX N/A
- 52 Week Low
- SGRP $0.70
- SCYX $1.19
- 52 Week High
- SGRP $3.12
- SCYX $3.07
- Technical
- Relative Strength Index (RSI)
- SGRP 27.72
- SCYX 29.63
- Support Level
- SGRP $2.19
- SCYX $1.25
- Resistance Level
- SGRP $2.46
- SCYX $1.37
- Average True Range (ATR)
- SGRP 0.05
- SCYX 0.07
- MACD
- SGRP -0.02
- SCYX -0.01
- Stochastic Oscillator
- SGRP 20.69
- SCYX 4.17
About SGRP SPAR Group Inc.
SPAR Group Inc is a supplier of merchandising and other marketing services. It also provides range of services to retailers, consumer goods manufacturers and distributors around the globe. The company divides its operations into three reportable regional segments: Americas, which is comprised of United States, Canada, Brazil and Mexico; Asia-Pacific (APAC), which is comprised of Japan, China, and India; and Europe, Middle East and Africa (EMEA), which is comprised of South Africa. It generates maximum revenue from Americas.
About SCYX SCYNEXIS Inc.
SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against a broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.